Sarcomas | Specialty

Clinical Trial Could Change Surgical Management of Metastatic Osteosarcoma

April 28th 2020

R. Lor Randall, MD, FACS, discusses current approaches in the surgical management of patients with osteosarcoma that has metastasized to the lungs.

Avapritinib Falls Short in VOYAGER Phase 3 GIST Trial

April 28th 2020

Avapritinib did not improve progression-free survival versus regorafenib in previously treated patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor, missing the primary end point of the phase 3 VOYAGER trial.

Pexidartinib Shakes Up TGCT Treatment, But Questions Remain

April 26th 2020

John A. Abraham, MD, FACS, discusses the role of surgery in the treatment of tenosynovial giant cell tumor, key challenges faced in this space, and the emergence of pexidartinib.

Avapritinib Takes Step Toward Chinese Approval for GIST

April 23rd 2020

The China National Medical Products Administration has accepted a new drug application for avapritinib for 2 indications in gastrointestinal stromal tumors.

Expert Explains Significance of Tazemetostat FDA Approval for Rare Sarcoma

April 23rd 2020

Brian Van Tine, MD, PhD, discusses what tazemetostat’s approval brings to the treatment landscape for patients with epithelioid sarcoma.

Dr. D'Amato on the Emerging Role of Next-Generation Sequencing in Sarcoma

April 11th 2020

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

Ivosidenib Shows Durable Disease Control in Advanced IDH1-Mutant Chondrosarcoma

April 10th 2020

Ivosidenib showed minimal toxicity, substantial 2-hydroxyglutarate reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone.

Avapritinib Approval Sought in Taiwan for PDGFRA Exon 18+ GIST

March 27th 2020

A new drug application has been submitted to the Taiwan Food and Drug Administration for avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring PDGFRA exon 18 mutations, including PDGFRA D842V mutations, according to CStone Pharmaceuticals, a partner of Blueprint Medicines.

Prevention of Pathologic Fractures After Soft Tissue Sarcomas by the Spread of Awareness

March 25th 2020

R. Lor Randall, MD, FACS, discusses the occurrence, treatment, and prevention methods of pathologic fractures in patients with soft tissue sarcomas.

The Future of Treatment for Soft Tissue Diseases

March 25th 2020

GIST Treatment: Durability of Response and Challenges

March 25th 2020

Use of Targeted Therapy in GIST Mutations

March 25th 2020

Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020

Soft Tissue Sarcoma: Unmet Needs

March 25th 2020

The Prognostic Value of Molecular Testing

March 25th 2020

Switching Therapy: Secondary Mutations and Resistance

March 25th 2020

Current Treatment Landscape of Soft Tissue Sarcoma

March 25th 2020

Diagnostic Testing Procedure for Soft Tissue Sarcoma

March 25th 2020

NY-ESO-1, MAGE-A4 Among Key Targets in Sarcoma Research

March 17th 2020

Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts

March 17th 2020

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.